Pacmilimab
Based on 1 Customer Validation
Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 95.00%
- CAS. Nr.: 2145091-51-4
- Molecular Weight:152.6 kDa
-
Speicherung:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
B7-H1/PD-L1/CD274
In Vivo
Pacmilimab accumulates in murine PD-L1-expressing tumors with minimal uptake in peripheral, non-cancerous lymphoid tissue, consistent with limited uptake in non-tumor PD-L1-expressing tissues and protection against autoimmunity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4 kappa
Anwendung
ELISA, FACS, Functional assay
Chemical Information
-
CAS. Nr. 2145091-51-4
-
Appearance Liquid
-
Molecular Weight 152.6 kDa
-
Color Colorless to light yellow
-
SMILES
[Pacmilimab]
-
Synonyms
CX-072
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)